

THE LANCET

Respiratory Medicine

Supplementary appendix

This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors.

Supplement to: Shostak Y, Shafran N, Heching M, et al. Early humoral response among lung transplant recipients vaccinated with BNT162b2 vaccine. *Lancet Respir Med* 2021; published online May 5. [http://dx.doi.org/10.1016/S2213-2600\(21\)00184-3](http://dx.doi.org/10.1016/S2213-2600(21)00184-3).

Appendix

All participants provided written informed consent. The study was approved by the review board at the Rabin Medical Center.

Acknowledgements: we thank Ilana Bakal our transplant coordinator, Hilla Levi, Yulia Larin, Helen Yeshayahu and Liora Yehoshua from research unit at pulmonary institute, and Professor Amir Shlomain for assistance in data management and statistical analyses.

Figure 1: A column scatter plot graph representing BNT162b2 induced S1-IgG antibody levels (AU/ml) in lung and heart-lung transplant recipients during the first (baseline) and the second (within the third week after the second vaccine dose) visits. The bars represent geometrical mean \pm standard deviation of both, seropositive and seronegative groups.




Table S1: Additional demographic and clinical characteristics of study participants, stratified by seropositivity to anti-spike IgG antibodies after two vaccine doses

	Seropositive (%) n=31	Seronegative (%) n=137	Odds ratio (95% CI)	P value
Rate of seropositivity after the first vaccine dose^a	6 (4)	154 (96)		<0.0001
Laboratory result^{b,c}				
Creatinine	1.24 (0.95-1.49)	1.26 (1.01-1.55)	0.76 (0.30-1.95) ^d	0.58
CRP	0.28 (0.11-0.64)	0.43 (0.22-0.80)	0.60 (0.25-1.42) ^e	0.24
WBC (K/microL)	7.62 (6.11-8.99)	7.96 (6.80-9.37)	0.98 (0.20-4.78) ^f	0.98
Lymphocyte (K/microL)	1.86 (1.5-2.5)	1.83 (1.40-2.36)	0.87 (0.18-4.21) ^g	0.24
Globulin (g/dL)	2.43 (2.26-2.80)	2.33 (2.16-2.56)	0.53 (0.14-1.89) ^h	0.02
Transplant etiology				
COPD	4 (12.9)	27 (19.7)	0.60 (0.19-1.87)	0.37
IPF	12 (38.7)	59 (43.1)	0.83 (0.37-1.85)	0.65
CF	7 (22.6)	13 (9.5)	2.78 (1.00-7.69)	0.05
Bronchiectasis	4 (12.9)	10 (7.3)	1.88 (0.54-6.44)	0.24
PHTN	2 (6.5)	4 (2.9)	2.29 (0.4-13.12)	0.30

Abbreviations: CRP, C-reactive protein; WBC, white blood cells; Lymphocyte, absolute lymphocyte count; COPD, chronic obstructive pulmonary disease; IPF, idiopathic pulmonary fibrosis; CF, cystic fibrosis; PHTN, pulmonary hypertension.

^a 21-28 days after the first vaccine dose. At this time point 160 patients were included.

^b Data presented in median and IQR

^c Mean values calculated from the last three successive blood tests during clinic follow-up. Time period for values collection for each patient was between 1-5 months prior vaccination. No missing values were registered.

^d Comparison of more or less than of 1.5 mg/dL, this value was chosen to define renal failure

^e Comparison of more or less than of 0.5 mg/dL, this value was chosen since it is the upper limit of normal at RMC lab

^f Comparison of more or less than 4500 cells/microL, this value was chosen since it is the lower limit of normal (LLN) at RMC lab

^g Comparison of more or less then of 1000 cells/microL, this value was chosen since it is the LLN at RMC lab

^h Comparison of more or less then of 2.1g/dL, this value was chosen since it is the LLN at RMC lab